Concepedia

Donata Vitagliano

DV

Statistics

Publications

22

Citations

2.2K

H-Index

20

Active since

1999

Affiliations

University of Naples Federico II(Current)

Institute for Experimental Endocrinology and Oncology

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Regione Campania

AstraZeneca (United Kingdom)

Donata Vitagliano is an author at University of Naples Federico II specializing in medicine, molecular oncology, and oncology.

Publications per year

1999–2017

22

Publications

22

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 570 citations

, , +17

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Teresa Troiani, Erika Martinelli, Stefania Napolitano et al. · Clinical Cancer Research · 2013 · 145 citations · Full text

, , +17

The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 135 citations

, , +17

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer

Carminia Maria Della Corte, Claudio Bellevicine, Giovanni Vicidomini et al. · Clinical Cancer Research · 2015 · 119 citations · Full text

, , +17

Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

Floriana Morgillo, Ferdinando Carlo Sasso, Carminia Maria Della Corte et al. · Clinical Cancer Research · 2013 · 117 citations

, , +14

1–5 of 22